Clinical trial NCT02174445: An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Official title: Imatinib Continuation Versus Nilotinib 300 mg Twice Daily in Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase and Major Molecular Re-sponse (MMR) Without Molecular Response ≥ 4.5 Log (MR4.5) Receiving Imatinib at a Dose of 400 to 800 mg Daily. An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Chronic Myeloid Leukemia
Keywords: Patients with CML in chronic phase
Imatinib
Nilotinib
Lead sponsor: University Hospital Freiburg
Sponsor class: OTHER
Collaborators: name: Novartis
First posted: 2014-06-25
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open-label, multicenter, randomised phase 3b clinical trial of Imatinib 400 to 800 mg daily versus Nilotinib 300 mg two times daily in chronic phase CML patients with confirmed MMR without MR4.5

Detailed description: This is an open-label, multicenter, randomised phase 3b clinical trial of Imatinib 400 to 800 mg daily versus Nilotinib 300 mg two times daily in chronic phase CML patients with confirmed MMR without MR4.5 (after having received Imatinib 400 to 800 mg daily for at least 18 months) to determine the proportion of patients with confirmed MR4 after two years. Patients in treatment arm A (Imatinib) who do not achieve confirmed MR4 2 years after randomisation will be offered cross-over from Imatinib 400 to 800 mg daily to Nilotinib 300 mg twice daily. One hundred thirty-two (132) patients will be included and randomised 1:1 to each treatment arm.

The study will be stratified by duration of Imatinib treatment before screen-ing (≤36 months / \>36 months) as well as by the level of response at inclusion (MMR / MR4).

Eligibility criteria: Inclusion criteria:

1. Signed written informed consent
2. Male or female patients aged \>=18 years (without upper limit of age)
3. ECOG performance status of 0 to 2
4. CML in chronic phase, with chronic phase defined as blasts \< 15% in blood and/or bone marrow and peripheral blood basophils \< 20% and platelets ≥ 100 G/L
5. Pretreatment with Imatinib with a treatment duration of at least 18 months at a dosage of 400 to 800 mg daily
6. Major molecular response (MMR) without molecular response ≥ 4.5 log (MR4.5), i.e. BCR-ABL\>0.0032% and ≤0.1% IS confirmed by central la-boratory at screening will be required for randomisation
7. Patients must have a serum Creatinine of ≤ 1.5 x ULN, SGOT ≤ 1.5 x ULN, total bilirubin ≤ 1.5 x ULN (except known M. Gilbert), and Lipase ≤ 1.5 x ULN
8. Women of child-bearing potential defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months, must have a negative serum pregnancy test during screening period. Male and fe-male patients of reproductive potential must agree to employ highly ef-fective methods of birth control throughout the study and for up to 3 months following discontinuation of study drug. Appropriate methods are e.g. a highly effective method of first choice, i.e. a method with a low failure rate (less than 1% per year) like sexual abstinence, com-bined oral contraceptives, implants, injectable, some Intra Uterine Devices (IUDs), vasectomized partner, in combination with a method of second choice like condom, diaphragm, or cup pessary with spermicidal foam/gel/film/cream/suppository.

Exclusion Criteria:

1. Any previous treatment for CML other than Hydroxyurea, Imatinib or Interferon alpha
2. Evidence of features of accelerated or blast phase at any time
3. Previous loss of hematologic or cytogenetic response
4. Concomitant medications known to be strong inducers or inhibitors of P450 Isoenzyme CYP3A4
5. Finding of a secondary BCR-ABL resistance mutation at any time
6. History of intolerance to Imatinib that required treatment interruption longer than 4 weeks (cumulative) or dose reductions to less than 400 mg daily for longer than 4 weeks (cumulative) during the last 12 months before informed consent
7. Patients who had prior allogeneic, syngeneic, or autologous bone mar-row transplant or stem cell transplant
8. Patients unwilling to or unable to comply with the planned therapeutic intervention or to comply with the study treatment visits including blood sample collection within the protocol
9. History of pancreatitis, chronic inflammatory diseases or autoimmune diseases
10. Patients who underwent solid organ transplantation
11. Impaired cardiac function, including any of the following:

    * History of or presence of complete left bundle branch block, right bundle branch block plus left anterior hemi block, bifascicular block in screening ECG
    * Use of a cardiac pacemaker
    * ST depression of \> 1mm in 2 or more leads and/or T wave inver-sions in 2 or more contiguous leads in screening ECG
    * Congenital Long QT Syndrome
    * QTc\> 450 msec in the screening ECG
    * QT prolonging concomitant medication
    * History of or presence of significant ventricular or atrial tachy-arrhythmia in screening ECG
    * History of or presence of clinically significant resting bradycardia (\< 50 beats per minute)
    * Myocardial infarction within 12 months prior to informed consent
    * Unstable angina diagnosed or treated during the past 12 months before informed consent
    * Other clinically significant heart disease (e.g., congestive heart fail-ure, uncontrolled hypertension, history of labile hypertension)
12. Known HIV and/or hepatitis B or C infection (testing is not mandatory)
13. Other malignancies within the past 3 years before informed consent except for adequately treated carcinoma of the cervix and basal or squamous cell carcinoma of the skin
14. Women who are pregnant or breast feeding
15. Male/female patients of reproductive potential unwilling to practice a highly effective method of birth control
16. History of noncompliance to medical regimens
17. Treatment with another investigational product during this study or during the last 30 days prior to informed consent

Primary outcomes:
measure: Proportion of patients with confirmed MR4 after two years of study treatment
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Aachen
country: Germany
facility: Universitätsklinikum Aachen
city: Augsburg
country: Germany
facility: Praxis Dr. Bruder / Dr. Heinrich / Prof. Bangerter
city: Bonn
country: Germany
facility: Universitätsklinikum Bonn
city: Dresden
country: Germany
facility: Gemeinschaftspraxis
city: Erfurt
country: Germany
facility: Praxis Dr. Hauch
city: Erlangen
country: Germany
facility: Internistische Schwerpunktpraxis Erlangen oncosearch
city: Essen
country: Germany
facility: Praxis für Hämatologie/Onkologie Dres. Rudolph, Sengpiel, von Verschuer
city: Freiburg
country: Germany
facility: University Medical Center
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg-Eppendorf
city: Jena
country: Germany
facility: Universitätsklinikum Jena
city: Köln
country: Germany
facility: Universitätsklinik Köln
city: Magdeburg
country: Germany
facility: Gemeinschaftspraxis Hämatologie/Onkologie
city: Mannheim
country: Germany
facility: Klinikum Mannheim GmbH Universitätsklinikum
city: Munich
country: Germany
facility: Überörtliche Gemeinschaftspraxis Hämato-Onkologie Pasing/Fürstenfeldbruck
city: München
country: Germany
facility: Klinikum rechts der Isar, Technische Universität München
city: Oldenburg
country: Germany
facility: Onkologische Praxis Oldenburg
city: Saarbrucken
country: Germany
facility: Medizinische Statistik Saarbrücken, GbR
city: Ulm
country: Germany
facility: Universitätsklinikum Ulm
Study officials:
affiliation: University Hospital Freiburg
name: Nikolas von Bubnoff, Professor
role: PRINCIPAL_INVESTIGATOR
References: